MedTrace Logo

Study to Assess Antioxidant Efficacy of Spirulina on oxLDL and Lipids Metabolism on Subjects With Metabolic Syndrome

NCT02817620 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2017-09-18

No results posted yet for this study

Summary

The purpose of this pilot study is to assess the beneficial effect of a spirulina water extract (product named Spirulysat®) compared to a placebo in the blood level ratio of oxidized LDL / total LDL cholesterol in subjects with metabolic syndrome after 12 weeks of consumption

Conditions

  • Metabolic Syndrome

Interventions

DIETARY_SUPPLEMENT

Spirulysat®

DIETARY_SUPPLEMENT

Placebo

Sponsors & Collaborators

  • Biofortis Mérieux NutriSciences

    collaborator OTHER

  • Algosource

    lead INDUSTRY

Principal Investigators

  • Sophie SCHMID · Biofortis Mérieux NutriSciences

  • David GENDRE · Biofortis Mérieux NutriSciences

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-08-24
Primary Completion
2017-09-14
Completion
2017-09-14

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02817620 on ClinicalTrials.gov